Hepatotoxicity of ketoconazole in Sprague-Dawley rats: Glutathione depletion, flavin-containing monooxygenases-mediated bioactivation and hepatic covalent binding

Xenobiotica

Volumn 33, Issue 4, 2003, Pages 429-441

  Rodriguez, R J ^a   Buckholz, C J ^a  

^a OREGON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; GLUTATHIONE; KETOCONAZOLE; UNSPECIFIC MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; COVALENT BOND; DRUG ACTIVITY; DRUG EFFECT; DRUG INDUCED DISEASE; IMMUNE RESPONSE; LIVER INJURY; LIVER PARENCHYMA; LIVER TOXICITY; MALE; NONHUMAN; OXIDATIVE STRESS; RAT; STRUCTURE ANALYSIS;

ALANINE TRANSAMINASE; ANIMALS; ANTIFUNGAL AGENTS; BIOTRANSFORMATION; GLUTATHIONE; HEPATITIS, TOXIC; INJECTIONS, INTRAPERITONEAL; KETOCONAZOLE; LIVER; MALE; MICROSOMES, LIVER; MONOAMINE OXIDASE; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA;

EID: 0038171246     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/0049825031000072243     Document Type: Article

References (43)

1. BACK, D. J., TJIA, J. F. and ABEL, S. M., 1992, Azoles, allylamines and drug metabolism. British Journal of Dermatology, 126, 14-18.
2. BAXTER, J. G., BRASS, C., SCHENTAG, J. J. and SLAUGHTER, R. L., 1986, Pharmacokinetics of ketoconazole administered intravenously to dogs and orally as tablet and solution to humans and dogs. Journal of Pharmaceutical Sciences, 75, 443-447.
3. BENSON, G. D., ANDERSON, P. K., COMBES, B. and ISHAK, K. G., 1988, Prolonged jaundice following ketoconazole-induced hepatic injury. Digestive Diseases Sciences, 33, 240-246.
4. BERCOFF, E., BERNUAU, J., DEGOTT, C., KALIS, B., LAMAIRE, A., TILLY, H., RUEFF, B. and BENHAMOU, J. P., 1985, Ketoconazole-induced fulminant hepatitis. Gut, 26, 636-638.
5. BOK, R. A. and SMALL, E. J., 1999, The treatment of advanced prostate cancer with ketoconazole: safety issues. Drug Safety, 20, 451-458.
6. BRASS, C., GALGIANI, J. N., BLASCHKE, T. F., DEFELICE, R., O'REILLY, R. A. and STEVENS, D. A., 1982, Disposition of ketoconazole, an oral antifungal, in humans. Antimicrobial Agents and Chemotherapy, 21, 151-158.
7. BRUSKO, C. S. and MARTEN, J. T., 1991, Ketoconazole hepatotoxicity in a patient treated for environmental illness and systemic candidiasis. Annals of Pharmacotherapy, 25, 1321-1325.
8. CASHMAN, J. R., XIONG, Y. N., XU, L. and JANOWSKY, A., 1999, N-oxygenation of amphetamine and methamphetamine by the human flavin-containing monooxygenase (Form 3): role in bioactivation and detoxication. Journal of Pharmacology and Experimental Therapeutics, 288, 1251-1260.
9. CAUWENBERGH, G., 1989, Safety aspects of ketoconazole, the most commonly used systemic antifungal. Mycoses, 32, 59-63.
10. CHIEN, R.-N., YANG, L.-J., LIN, P.-Y. and LIAW, Y.-F., 1997, Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study. Hepatology, 25, 103-107.
11. DANESHMEND, T. K. and WARNOCK, D. W., 1988, Clinical pharmacokinetics of ketoconazole. Clinical Pharmacokinetics, 14, 13-34.
12. DANESHMEND, T. K., WARNOCK, D. W., ENE, M. D., JOHNSON, E. M. and PARKER, G., 1983, Multiple dose pharmacokinetics of ketoconazole and their effects on antipyrine kinetics in man. Journal of Antimicrobics and Chemotheraphy, 12, 185-188.
13. DE COSTER, R., CAERS, I., COENE, M. C., AMERY, W., BEERENS, D. and HAELTERMAN, C., 1986, Effects of high dose ketoconazole therapy on the main plasma testicular and adrenal steroids in previously untreated prostatic cancer patients. Clinical Endocrinology, 24, 657-664.
14. DE COSTER, R., WOUTERS, W. and BRUYNESEELS, J., 1996, P450-dependent enzymes as targets for prostate cancer therapy. Journal of Steroid Biochemical and Molecular Biology, 56, 133-143.
15. DUARTE, P. A., CHOW, C. C., SIMMONS, F. and RUSKIN, J., 1984, Fatal hepatitis associated with ketoconazole therapy. Archives of Internal Medicine, 144, 1069-1070.
16. GASCOIGNE, E. W., BARTON, G. J., MICHAELS, M., MEULDERMANS, W. and HEYKANTS, J., 1981, The kinetics of ketoconazole in animals and man. Clinical Research Reviews, 1, 177-187.
17. GRADON, J. D. and SEPKOWITZ, D. V., 1990, Massive hepatic enlargement with fatty change associated with ketoconazole. Annals of Pharmacotherapy, 24, 1175-1176.
18. HEEL, R. C., BROGDEN, R. N., CARMINE, A., MORLEY, P. A., SPEIGHT, T. M. and AVERY, G. S., 1982, Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections. Drugs, 23, 1-36.
19. HOGBERG, J. and KRISTOFERSON, A., 1977, A correlation between glutathione levels and cellular damage in isolated hepatocytes. European Journal of Biochemistry, 74, 77-82.
20. HUANG, Y. C., COLAIZZI, J. L., BIERMAN, R. H., WOESTENBORGHS, R. and HEYKANTS, J., 1986, Pharmacokinetics and dose proportionality of ketoconazole in normal volunteers. Antimicrobial Agents and Chemotheraphy, 30, 206-210.
21. IIT, Research Institute, 1999, Chemoprevention - prostate cancer. Life Sciences Newsletter, Fall, 2-4.
22. JACOBS, P. H. and NALL, L., 1988, The action and safety of ketoconazole: a brief literature review. CUTIS, 42, 276-282.
23. JAEGER, R. J., CONOLLY, R. B. and MURPHY, S. D., 1973, Diurnal variation of hepatic glutathione concentration and its correlation with 1,1-dichloroethylene inhalation toxicity in rats. Research Communication in Chemical Pathology and Pharmacology, 6, 465-471.
24. JANSSEN, 1995, Product monograph: Nizoral®, Ketoconazole (Titusville, NJ: Janssen Pharmaceuticals).
25. JANSSEN, P. A. and SYMOENS, J. E., 1983, Hepatic reactions during ketoconazole treatment. American Journal of Medicine, 74, 80-85.
26. KNIGHT, T. E., SHIKUMA, C. Y. and KNIGHT, J., 1991, Ketoconazole-induced fulminant hepatitis necessitating liver transplantation. Journal of the American Academy of Dermatology, 25, 398-400.
27. KUROKOHCHI, K., NISHIOKA, M. and ICHIKAWA, Y., 1992, Inhibition mechanism of reconstituted cytochrome P-450s cc-linked monooxygenase system by antimycotic reagents and other inhibitors. Journal of Steroid Biochemistry and Molecular Biology, 42, 287-292.
28. LEWIS, J. H., ZIMMERMAN, H. J., BENSON, G. D. and ISHAK, K. G., 1984, Hepatic injury associated with ketoconazole therapy. Gastroenterology, 86, 503-513.
29. MACNAIR, A. L., GASCOIGNE, E., HEAP, J., SCHUEMAN, V. and SYMOENS, J., 1981, Hepatitis and ketoconazole therapy. British Medical Journal, 283, 1058-1059.
30. ROBERTS, J. C. and FRANCETIC, D. J., 1993, The importance of sample preparation and storage in glutathione analysis. Analytical Biochemistry, 211, 183-187.
31. RODRIGUES, A. D., GIBSON, G. G., IONNIDES, C. and PARKE, D. V., 1987a, Interactions of imidazole antifungal agents with purified cytochrome P-450 proteins. Biochemical Pharmacology, 36, 4277-4281.
32. RODRIGUES, A. D., LEWIS, D. F. V., IOANNIDES, C. and PARKE, D. V., 1987b, Spectral and kinetic studies of the interaction of imidazole anti-fungal agents with microsomal cytochrome P-450. Xenobiotica, 17, 1315-1327.
33. RODRIGUEZ, R. J. and ACOSTA, D., 1997a, N-deacetyl ketoconazole-induced hepatotoxicity in a primary culture system of rat hepatocytes. Toxicology, 117, 123-131.
34. RODRIGUEZ, R. J. and ACOSTA, D., 1997b, Metabolism of ketoconazole and deacetylated ketoconazole by rat hepatic microsomes and flavin-containing monooxygenases. Drug Metabolism and Disposition, 25, 772-777.
35. RODRIGUEZ, R. J., PROTEAU, P. J., MARQUEZ, B., HETHERINGTON, C. L., BUCKHOLZ, C. J. and O'CONNELL, K. L., 1999, Flavin-containing monooxygenase-mediated metabolism of N-deacetyl ketoconazole by rat hepatic microsomes. Drug Metabolism and Disposition, 27, 880-886.
36. STRICKER, B. H. C., BLOK, A. P. R., BRONKHORST, F. B., VAN PARYS, G. E. and DESMET, V. J., 1986, Ketoconazole-associated hepatic injury a clinicopathological study of 55 cases. Journal of Hepatology, 3, 399-406.
37. SUGAR, A. M., ALSIP, S. G., GALGIANI, J. N., GRAYBILL, J. R., DISMUKES, W. E., CLOUD, G. A., CRAVEN, P. C. and STEVENS, D. A., 1987, Pharmacology and toxicity of high-dose ketoconazole. Antimicrobial Agents and Chemotheraphy, 31, 1874-1878.
38. SVEJGAARD, E. and RANEK, L., 1982, Hepatic dysfunction and ketoconazole therapy. Annals of Internal Medicine, 96, 788-789.
39. VAN PARYS, G., EVENEPOEL, C., VAN DAMME, B. and DESMET, V. J., 1987, Ketoconazole-induced hepatitis: a case with a definite cause-effect relationship. Liver, 7, 27-30.
40. VANDEN BOSSCHE, H., MARICHAL, P., GORRENS, J., GEERTS, J. and JANSSEN, P. A., 1988, Basis for the search for new antifungal drugs. Annals of the New York Academy of Sciences, 544, 191-207.
41. WHITEHOUSE., L. W., MENZIES, A., DAWSON, B., ZAMECNIK, J. and SY, W. W., 1990, Deacetylated ketoconazole: a major ketoconazole metabolite isolated from mouse liver. Journal of Pharmaceutical Biomedical Analysis, 8, 603-606.
42. ZIEGLER, D. M., 1980, Microsomal flavin-containing monoxygenase: oxygenation of nucleophilic nitrogen and sulfur compounds. Enzymatic Basis of Detoxication, 1, 201-227.
43. ZIEGLER, D. M., 1988. Flavin-containing monooxygenases: catalytic mechanism and substrate specificities. Drug Metabolism Reviews, 19, 1-32.